KR20010042816A - 에어로졸 제약 제형 - Google Patents

에어로졸 제약 제형 Download PDF

Info

Publication number: KR20010042816A
Authority: KR; South Korea
Prior art keywords: pharmaceutical formulation; suspension; aerosol pharmaceutical; surfactant; particles
Prior art date: 1998-04-18

Application number

KR1020007011572A

Other languages

English (en)

Korean (ko)

Inventor

파스칼 카바일롱

나탈리에 로흐카

올리비에 루이

파트릭 로지에

Original Assignee

그레이엄 브레레톤, 레슬리 에드워즈

글락소 그룹 리미티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-18

Filing date

1999-04-15

Publication date

2001-05-25

1998-04-18 Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en

1998-07-08 Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en

1999-04-15 Application filed by 그레이엄 브레레톤, 레슬리 에드워즈, 글락소 그룹 리미티드 filed Critical 그레이엄 브레레톤, 레슬리 에드워즈

2001-05-25 Publication of KR20010042816A publication Critical patent/KR20010042816A/ko

Links

239000000203 mixture Substances 0.000 title claims abstract description 38
238000009472 formulation Methods 0.000 title claims abstract description 16
239000008249 pharmaceutical aerosol Substances 0.000 title claims 2
239000002245 particle Substances 0.000 claims abstract description 113
239000003814 drug Substances 0.000 claims abstract description 88
239000007921 spray Substances 0.000 claims abstract description 63
239000004094 surface-active agent Substances 0.000 claims abstract description 42
239000000443 aerosol Substances 0.000 claims abstract description 40
239000011248 coating agent Substances 0.000 claims abstract description 36
238000000576 coating method Methods 0.000 claims abstract description 36
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 35
229940124597 therapeutic agent Drugs 0.000 claims abstract description 33
238000000034 method Methods 0.000 claims abstract description 32
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 32
230000002685 pulmonary effect Effects 0.000 claims abstract description 9
239000000725 suspension Substances 0.000 claims description 67
229940079593 drug Drugs 0.000 claims description 55
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 49
235000010445 lecithin Nutrition 0.000 claims description 49
239000000787 lecithin Substances 0.000 claims description 49
229940067606 lecithin Drugs 0.000 claims description 49
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 39
239000008101 lactose Substances 0.000 claims description 37
229940038482 beclomethasone dipropionate monohydrate Drugs 0.000 claims description 35
239000003380 propellant Substances 0.000 claims description 26
238000001694 spray drying Methods 0.000 claims description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
239000002609 medium Substances 0.000 claims description 20
238000011049 filling Methods 0.000 claims description 16
239000012298 atmosphere Substances 0.000 claims description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
239000002904 solvent Substances 0.000 claims description 11
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 10
-1 polyoxyethylene Polymers 0.000 claims description 10
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
229950000210 beclometasone dipropionate Drugs 0.000 claims description 6
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
229960004017 salmeterol Drugs 0.000 claims description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
238000005507 spraying Methods 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
229960000289 fluticasone propionate Drugs 0.000 claims description 3
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 3
150000004676 glycans Chemical class 0.000 claims description 3
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
229920001282 polysaccharide Polymers 0.000 claims description 3
239000005017 polysaccharide Substances 0.000 claims description 3
235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
239000008158 vegetable oil Substances 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
239000005642 Oleic acid Substances 0.000 claims description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
229920001213 Polysorbate 20 Polymers 0.000 claims description 2
239000004147 Sorbitan trioleate Substances 0.000 claims description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
239000003945 anionic surfactant Substances 0.000 claims description 2
229960000686 benzalkonium chloride Drugs 0.000 claims description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
239000003093 cationic surfactant Substances 0.000 claims description 2
229960000541 cetyl alcohol Drugs 0.000 claims description 2
229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
235000005687 corn oil Nutrition 0.000 claims description 2
239000002285 corn oil Substances 0.000 claims description 2
235000012343 cottonseed oil Nutrition 0.000 claims description 2
239000002385 cottonseed oil Substances 0.000 claims description 2
239000008121 dextrose Substances 0.000 claims description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
230000000694 effects Effects 0.000 claims description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
229940093471 ethyl oleate Drugs 0.000 claims description 2
239000012458 free base Substances 0.000 claims description 2
229940068939 glyceryl monolaurate Drugs 0.000 claims description 2
229940075507 glyceryl monostearate Drugs 0.000 claims description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
229940074928 isopropyl myristate Drugs 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
239000002736 nonionic surfactant Substances 0.000 claims description 2
239000003921 oil Substances 0.000 claims description 2
235000019198 oils Nutrition 0.000 claims description 2
229960002969 oleic acid Drugs 0.000 claims description 2
235000021313 oleic acid Nutrition 0.000 claims description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000004006 olive oil Substances 0.000 claims description 2
235000008390 olive oil Nutrition 0.000 claims description 2
GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 claims description 2
238000004806 packaging method and process Methods 0.000 claims description 2
229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
229920000053 polysorbate 80 Polymers 0.000 claims description 2
229960002052 salbutamol Drugs 0.000 claims description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
239000001593 sorbitan monooleate Substances 0.000 claims description 2
235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
229940035049 sorbitan monooleate Drugs 0.000 claims description 2
235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
229960000391 sorbitan trioleate Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
229940012831 stearyl alcohol Drugs 0.000 claims description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
235000020238 sunflower seed Nutrition 0.000 claims description 2
229940072958 tetrahydrofurfuryl oleate Drugs 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims 6
238000010298 pulverizing process Methods 0.000 claims 3
HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 claims 1
229920005682 EO-PO block copolymer Polymers 0.000 claims 1
125000000129 anionic group Chemical group 0.000 claims 1
NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 claims 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
239000007789 gas Substances 0.000 description 30
239000000463 material Substances 0.000 description 25
QHQJZIXSVLFOHD-LYRZEVDOSA-N [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O QHQJZIXSVLFOHD-LYRZEVDOSA-N 0.000 description 20
238000002347 injection Methods 0.000 description 20
239000007924 injection Substances 0.000 description 20
238000003756 stirring Methods 0.000 description 14
239000007864 aqueous solution Substances 0.000 description 13
239000012530 fluid Substances 0.000 description 13
239000000047 product Substances 0.000 description 10
239000000843 powder Substances 0.000 description 8
239000000243 solution Substances 0.000 description 7
238000004320 controlled atmosphere Methods 0.000 description 6
238000000227 grinding Methods 0.000 description 6
239000011247 coating layer Substances 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000010410 layer Substances 0.000 description 2
239000006069 physical mixture Substances 0.000 description 2
239000011241 protective layer Substances 0.000 description 2
239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 description 1
JGZVUTYDEVUNMK-UHFFFAOYSA-N 5-carboxy-2',7'-dichlorofluorescein Chemical compound C12=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 JGZVUTYDEVUNMK-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
230000005465 channeling Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000011505 plaster Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005437 stratosphere Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

KR1020007011572A 1998-04-18 1999-04-15 에어로졸 제약 제형 KR20010042816A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9808152.4A GB9808152D0 (en)	1998-04-18	1998-04-18	Pharmaceutical aerosol formulation
GB9808152.4		1998-04-18
GBGB9814709.3A GB9814709D0 (en)	1998-07-08	1998-07-08	Pharmaceutical aerosol formulation
GB9814709.3		1998-07-08
PCT/EP1999/002535 WO1999053901A1 (en)	1998-04-18	1999-04-15	Pharmaceutical aerosol formulation

Publications (1)

Publication Number	Publication Date
KR20010042816A true KR20010042816A (ko)	2001-05-25

Family

ID=26313483

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020007011572A KR20010042816A (ko)	1998-04-18	1999-04-15	에어로졸 제약 제형

Country Status (30)

Country	Link
US (1)	US7521042B2 (is)
EP (1)	EP1073417B1 (is)
JP (1)	JP2002512183A (is)
KR (1)	KR20010042816A (is)
CN (1)	CN1145478C (is)
AP (1)	AP2000001961A0 (is)
AR (1)	AR018183A1 (is)
AT (1)	ATE228823T1 (is)
AU (1)	AU755066B2 (is)
BR (1)	BR9909736A (is)
CA (1)	CA2328882A1 (is)
CO (1)	CO5021210A1 (is)
DE (1)	DE69904312T2 (is)
DK (1)	DK1073417T3 (is)
EA (1)	EA200000956A1 (is)
EE (1)	EE200000608A (is)
ES (1)	ES2189410T3 (is)
HR (1)	HRP20000689A2 (is)
HU (1)	HUP0101608A2 (is)
ID (1)	ID27887A (is)
IL (1)	IL139087A0 (is)
IS (1)	IS5665A (is)
MA (1)	MA26621A1 (is)
NO (1)	NO20005218L (is)
NZ (1)	NZ507619A (is)
PE (1)	PE20000433A1 (is)
PL (1)	PL343491A1 (is)
PT (1)	PT1073417E (is)
TR (1)	TR200100144T2 (is)
WO (1)	WO1999053901A1 (is)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9616237D0 (en)	1996-08-01	1996-09-11	Norton Healthcare Ltd	Aerosol formulations
US6390291B1 (en) *	1998-12-18	2002-05-21	Smithkline Beecham Corporation	Method and package for storing a pressurized container containing a drug
US6119853A (en) *	1998-12-18	2000-09-19	Glaxo Wellcome Inc.	Method and package for storing a pressurized container containing a drug
DE60001492T2 (de) *	1999-04-14	2003-12-18	Glaxo Group Ltd., Greenford	Pharmazeutische aerosolformulierung
JP4380988B2 (ja) †	2000-11-30	2009-12-09	ヴェクトゥラリミテッド	医薬組成物に用いられる粒子の製造方法
PT1337240E (pt)	2000-11-30	2011-11-02	Vectura Ltd	Método de fabrico de partículas para utilização numa composição farmacêutica
JP4680601B2 (ja) *	2002-12-17	2011-05-11	メディミューン・エルエルシー	生物活性材料の高圧噴霧乾燥
ITMI20022674A1 (it) *	2002-12-18	2004-06-19	Chiesi Farma Spa	Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US6962006B2 (en) *	2002-12-19	2005-11-08	Acusphere, Inc.	Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2006528985A (ja) *	2003-05-19	2006-12-28	バクスター・インターナショナル・インコーポレイテッド	１つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
EP1833822A2 (en)	2004-08-16	2007-09-19	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
MX2007009656A (es) *	2005-02-10	2007-11-07	Glaxo Group Ltd	Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
CA2653384C (en)	2006-06-30	2017-03-14	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
US8425459B2 (en) *	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) *	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
CN104523661A (zh)	2009-02-06	2015-04-22	南加利福尼亚大学	含有单萜的治疗组合物
JP5809985B2 (ja)	2009-02-26	2015-11-11	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
US8541451B2 (en)	2009-07-15	2013-09-24	Theravance, Inc.	Crystalline freebase forms of a biphenyl compound
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
US8507734B2 (en)	2010-03-03	2013-08-13	Neonc Technologies Inc.	Pharmaceutical compositions comprising monoterpenes
US10888520B2 (en)	2010-06-08	2021-01-12	Kobe Gakuin Educational Foundation	Coated particle and method for producing coated particle
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
EP2883543B1 (en)	2010-08-27	2016-11-16	Neonc Technologies Inc.	Pharmaceutical compositions comprising perillyl alcohol carbamates
CN105616391B (zh)	2010-12-17	2021-03-19	尼昂克技术公司	使用异紫苏醇的方法和装置
CN102366405A (zh) *	2011-10-21	2012-03-07	江阴长风医药科技有限公司	以氢氟烷烃为抛射剂的氟替卡松丙酸酯气雾剂制剂
JP6231022B2 (ja) *	2012-02-28	2017-11-15	アイシューティカホールディングスインク．ＩｃｅｕｔｉｃａＨｏｌｄｉｎｇｓＩｎｃ．	吸入可能な医薬組成物
CN105142638B (zh)	2013-03-15	2020-08-28	维罗纳制药公司	药物组合
ES2682105T3 (es)	2014-05-12	2018-09-18	Verona Pharma Plc	Nuevo tratamiento
KR20170131405A (ko)	2015-02-12	2017-11-29	네온씨 테크놀로지스, 아이엔씨.	페릴릴 알코올 유도체를 포함하는 의약 조성물
CN106546751A (zh) *	2016-11-16	2017-03-29	广州华弘生物科技有限公司	用于检测oct4蛋白的酶联免疫试剂盒
EP3547836B1 (en)	2016-11-30	2024-08-21	University of Southern California	A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
EP4389765A3 (en)	2018-02-08	2024-08-21	University of Southern California	Methods of permeabilizing the blood brain barrier

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141674A (en) *	1984-03-08	1992-08-25	Phares Pharmaceutical Research N.V.	Methods of preparing pro-liposome dispersions and aerosols
ES2053549T3 (es) *	1986-08-11	1994-08-01	Innovata Biomed Ltd	Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
GB9024365D0 (en) *	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
EP0655237A1 (de) *	1993-11-27	1995-05-31	Hoechst Aktiengesellschaft	Medizinische Aerosolformulierung
GB9426252D0 (en) *	1994-12-24	1995-02-22	Glaxo Group Ltd	Pharmaceutical composition
DE69625813T2 (de) *	1995-06-12	2003-09-04	Ono Pharmaceutical Co. Ltd., Osaka	Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
GB9606677D0 (en) *	1996-03-29	1996-06-05	Glaxo Wellcome Inc	Process and device
JP2001507701A (ja) *	1996-12-31	2001-06-12	インヘイル・セラピューティック・システムズ・インコーポレーテッド	親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物

1999
- 1999-04-15 EA EA200000956A patent/EA200000956A1/ru unknown
- 1999-04-15 IL IL13908799A patent/IL139087A0/xx unknown
- 1999-04-15 CN CNB998072818A patent/CN1145478C/zh not_active Expired - Fee Related
- 1999-04-15 CA CA002328882A patent/CA2328882A1/en not_active Abandoned
- 1999-04-15 ID IDW20002392A patent/ID27887A/id unknown
- 1999-04-15 DK DK99916921T patent/DK1073417T3/da active
- 1999-04-15 ES ES99916921T patent/ES2189410T3/es not_active Expired - Lifetime
- 1999-04-15 AP APAP/P/2000/001961A patent/AP2000001961A0/en unknown
- 1999-04-15 EE EEP200000608A patent/EE200000608A/xx unknown
- 1999-04-15 AU AU35231/99A patent/AU755066B2/en not_active Ceased
- 1999-04-15 AR ARP990101747A patent/AR018183A1/es unknown
- 1999-04-15 BR BR9909736-2A patent/BR9909736A/pt not_active Application Discontinuation
- 1999-04-15 AT AT99916921T patent/ATE228823T1/de not_active IP Right Cessation
- 1999-04-15 CO CO99022532A patent/CO5021210A1/es unknown
- 1999-04-15 WO PCT/EP1999/002535 patent/WO1999053901A1/en not_active Application Discontinuation
- 1999-04-15 JP JP2000544308A patent/JP2002512183A/ja not_active Ceased
- 1999-04-15 EP EP99916921A patent/EP1073417B1/en not_active Expired - Lifetime
- 1999-04-15 NZ NZ507619A patent/NZ507619A/en unknown
- 1999-04-15 DE DE69904312T patent/DE69904312T2/de not_active Expired - Fee Related
- 1999-04-15 PT PT99916921T patent/PT1073417E/pt unknown
- 1999-04-15 MA MA25536A patent/MA26621A1/fr unknown
- 1999-04-15 KR KR1020007011572A patent/KR20010042816A/ko not_active Application Discontinuation
- 1999-04-15 TR TR2001/00144T patent/TR200100144T2/xx unknown
- 1999-04-15 PL PL99343491A patent/PL343491A1/xx unknown
- 1999-04-15 HU HU0101608A patent/HUP0101608A2/hu unknown
- 1999-04-16 PE PE1999000318A patent/PE20000433A1/es not_active Application Discontinuation
2000
- 2000-10-13 IS IS5665A patent/IS5665A/is unknown
- 2000-10-17 NO NO20005218A patent/NO20005218L/no not_active Application Discontinuation
- 2000-10-18 HR HR20000689A patent/HRP20000689A2/hr not_active Application Discontinuation
2003
- 2003-02-11 US US10/364,257 patent/US7521042B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1073417B1 (en)	2002-12-04
MA26621A1 (fr)	2004-12-20
AR018183A1 (es)	2001-10-31
PE20000433A1 (es)	2000-05-26
DK1073417T3 (da)	2003-03-24
HUP0101608A2 (hu)	2002-03-28
HRP20000689A2 (en)	2001-02-28
NZ507619A (en)	2003-05-30
ID27887A (id)	2001-05-03
TR200100144T2 (tr)	2001-06-21
EE200000608A (et)	2001-08-15
ES2189410T3 (es)	2003-07-01
JP2002512183A (ja)	2002-04-23
PT1073417E (pt)	2003-04-30
EA200000956A1 (ru)	2001-04-23
IL139087A0 (en)	2001-11-25
AU3523199A (en)	1999-11-08
PL343491A1 (en)	2001-08-27
BR9909736A (pt)	2000-12-19
EP1073417A1 (en)	2001-02-07
CA2328882A1 (en)	1999-10-28
DE69904312D1 (de)	2003-01-16
CN1305369A (zh)	2001-07-25
AP2000001961A0 (en)	2000-12-31
DE69904312T2 (de)	2003-10-16
CO5021210A1 (es)	2001-03-27
US7521042B2 (en)	2009-04-21
US20030157032A1 (en)	2003-08-21
IS5665A (is)	2000-10-13
NO20005218D0 (no)	2000-10-17
CN1145478C (zh)	2004-04-14
ATE228823T1 (de)	2002-12-15
WO1999053901A1 (en)	1999-10-28
NO20005218L (no)	2000-11-10
AU755066B2 (en)	2002-12-05

Publication	Publication Date	Title
KR20010042816A (ko)	2001-05-25	에어로졸 제약 제형
US7090831B1 (en)	2006-08-15	Pharmaceutical aerosol formulation
CA2094726C (en)	2002-01-15	Non-chlorofluorocarbon aerosol formulation comprising a particulate medicament
AU693632B2 (en)	1998-07-02	Proliposome powders for inhalation
KR100794060B1 (ko)	2008-01-10	에어로졸 약제 조성물
US20090142407A1 (en)	2009-06-04	Solid peptide preparations for inhalation and their preparation
JP2017505789A5 (is)	2020-01-23
EP0260241A1 (en)	1988-03-16	A new system for administration of liposomes to mammals
JP2000507862A (ja)	2000-06-27	粒状薬剤の吸入方法及び装置
CZ295521B6 (cs)	2005-08-17	Farmaceutický prostředek
JP2003530344A (ja)	2003-10-14	呼吸器疾患の治療
JP2002537249A (ja)	2002-11-05	喘息のためのホルモテロールおよびプロピオン酸フルチカゾンの組み合わせ
JPH07187996A (ja)	1995-07-25	医薬エーロゾル配合物
CZ176198A3 (cs)	1998-09-16	Nový prostředek
US6306368B1 (en)	2001-10-23	Aerosol formulation containing a particulate medicament
JP2002510311A (ja)	2002-04-02	トコフェロールにより安定化された吸引用プロリポソーム粉末
EP1674085A1 (en)	2006-06-28	Solid lipidic particles as pharmaceutically acceptable fillers or carriers for inhalation
MXPA00010159A (en)	2001-11-21	Pharmaceutical aerosol formulation

Legal Events

Date	Code	Title	Description
2004-04-16	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid